<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39549783</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-acute sequalae of COVID-19 three to twelve months after infection: Delta versus Omicron.</ArticleTitle><Pagination><StartPage>107302</StartPage><MedlinePgn>107302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2024.107302</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(24)00378-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Studies have shown temporal changes in Post-acute sequalae of COVID-19 (PASC) prevalence for early SARS-CoV-2 variants, though often lacking controls. This prospective study assesses the prevalence of symptoms in Delta and Omicron infected cases up to 12 months compared to population controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adult participants filled out three-monthly surveys (T0-T12) between July 2021 and August 2023. Cases were recruited with a positive SARS-CoV-2 test during Delta or Omicron domination. Population controls were randomly invited from the Dutch Personal Records Database. Participants indicated presence of 13 PASC-associated symptoms, and severity scores of fatigue, cognitive impairment, dyspnoea and pain. PASC prevalence was defined as the excess prevalence of having &#x2265; one PASC-associated symptom in cases compared to population controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PASC prevalence was 34.3% at T3 and decreased to 21.7% at T12 for Delta and decreased from 18.7% at T3 to 16.7% at T12 for Omicron. At T12 the difference between Delta and Omicron was not significant. Delta cases generally had higher excess symptom scores for fatigue, dyspnoea and cognitive impairment than Omicron.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In the first nine months after infection, PASC prevalence was higher for Delta than Omicron, but the difference reduced over time and approximated after twelve months.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Bruijn</LastName><ForeName>Sim&#xe9;on</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands. Electronic address: Simeon.de.bruijn@rivm.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tulen</LastName><ForeName>Anna D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodenburg</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Statistics, Data Science and Mathematical Modelling, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boshuizen</LastName><ForeName>Hendriek</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Statistics, Data Science and Mathematical Modelling, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schipper</LastName><ForeName>Maarten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Statistics, Data Science and Mathematical Modelling, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutubuki</LastName><ForeName>Elizabeth N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoop</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology and Amsterdam Public Health from the Amsterdam UMC, location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franz</LastName><ForeName>Eelco</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Maaden</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hof</LastName><ForeName>Susan van den</ForeName><Initials>SVD</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hoek</LastName><ForeName>Albert Jan</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijngaard</LastName><ForeName>Cees C van den</ForeName><Initials>CCVD</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Post Covid-19 Condition</Keyword><Keyword MajorTopicYN="N">Post-acute sequalae of COVID-19</Keyword><Keyword MajorTopicYN="N">twelve months</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>17</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>17</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>16</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39549783</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2024.107302</ArticleId><ArticleId IdType="pii">S1201-9712(24)00378-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>